What pfizer czech republic does

Pfizer Czech Republic (legal entity Pfizer, spol. s r.o.) is the Czech subsidiary of U.S. pharmaceutical major Pfizer Inc., incorporated as a private limited company in 1993 and headquartered in Prague 5 – Smíchov. It markets and distributes approximately 100 prescription medicines, biologics, and vaccines across therapeutic areas including oncology, cardiology, neurology, rheumatology, gastroenterology, antibiotics, rare diseases, and vaccines, with a particular emphasis on its pneumococcal (Prevenar 13, Prevenar 20), meningococcal (Nimenrix, Trumenba), tick-borne encephalitis (FSME-IMMUN), COVID-19 (Comirnaty JN.1/KP.2), and RSV (Abrysvo) vaccine franchises. Underlying technologies include the parent's mRNA vaccine platform co-developed with BioNTech, antibody-drug conjugates and bi-specific antibodies for oncology, and emerging AI applications for clinical trial data evaluation and rare disease diagnostic support.

The business model is prescription pharmaceutical sales routed through Czech wholesalers and pharmacies, with many vaccines fully reimbursed by public health insurance for specific age cohorts (Prevenar 20 for 65+, FSME-IMMUN for 50+, meningococcal vaccines for defined groups). The company runs an enterprise field sales motion supported by the PfizerPro healthcare-professional portal, a VPOIS public professional information service for product information, and dedicated inquiry channels for HCPs and patients. Beyond commercial activities, the Prague office hosts a Global Financial Services (GFS) center established in 2014 with an investment of nearly 180 million CZK and more than 200 financial experts, making the entity both a commercial distributor and a regional shared-services hub. It also allocates educational grants to non-profit healthcare organizations and partners with academic institutions such as the Faculty of Chemical Technology at the University of Pardubice.

Governance and industry positioning are reinforced through Pfizer's General Director MUDr. Pavel Sedláček, who also chairs the AIFP board of 35 innovative pharmaceutical companies for the 2024-2025 term. The entity operates under SÚKL regulatory oversight for clinical trials, pharmacovigilance, and product registration, and benefits from the parent's approximately $11 billion in annual global R&D investment, BCG top-10 most innovative company ranking (2021), and 175+ year heritage. Customer relationships are horizontal and diversified across therapeutic areas and the Czech healthcare system, with no individual customer concentration disclosed and products reserved for Czech residents per local regulatory requirements.

Name

pfizer czech republic

Legal name

Pfizer, spol. s r.o.

Website

https://pfizer.cz

Company type

Private

Founded year

1993

Operating status

Operating

Short description

Pfizer Czech Republic (Pfizer, spol. s r.o.) is a Prague-based subsidiary of Pfizer Inc. that markets and distributes roughly 100 prescription medicines and vaccines across oncology, cardiology, rare diseases, anti-infectives, and vaccines to the Czech healthcare system, while also hosting a 200+ person Global Financial Services center.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Vaccines & Cold-Chain Pharmaceutical Distributors (HLAIAJAG), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Prescription pharmaceuticals
• Vaccine development
• Oncology therapeutics
• Rare disease treatments
• Biopharmaceutical products

Headquarters

HQ city

Prague

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription pharmaceutical products including innovative medicines, biological drugs, and vaccines through pharmaceutical distribution channels. Markets approximately 100 medicinal products across multiple therapeutic areas in Czech Republic.
2. Vaccine Sales: Sales of various vaccines including pneumococcal (Prevenar 13, Prevenar 20), meningococcal (Nimenrix, Trumenba), tick-borne encephalitis (FSME-IMMUN), COVID-19 (Comirnaty), and RSV (Abrysvo) vaccines.
3. Educational Grants: Pfizer provides educational grants to non-profit healthcare organizations for health literacy and improved healthcare projects, demonstrating corporate social responsibility.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Pfizer Czech Republic develops, markets, and distributes approximately 100 prescription medicines, biological drugs, and vaccines across therapeutic areas including oncology, cardiovascular diseases, chronic inflammatory conditions, rare diseases, anti-infectives, and vaccines (COVID-19, pneumococcal, meningococcal, tick-borne encephalitis, RSV). The company distributes products through pharmaceutical wholesalers and pharmacies, and conducts clinical trials in Czech Republic.

Product overview

Pfizer Czech Republic offers a comprehensive portfolio of pharmaceutical products and vaccines. The company provides medications across multiple therapeutic areas including oncology, cardiovascular diseases, chronic inflammatory diseases, rare diseases, and anti-infective treatments. The vaccine portfolio includes COMIRNATY (COVID-19 mRNA vaccines), Prevenar 13/20 (pneumococcal vaccines), Nimenrix and Trumenba (meningococcal vaccines), FSME-IMMUN (tick-borne encephalitis vaccine), and ABRYSVO (RSV vaccine). The company also offers medical devices such as the MYCLIC pen accessory and maintains a public professional information service (VPOIS) for its registered medicinal products. Pfizer also conducts clinical trials in the Czech Republic across various therapeutic areas.

Differentiator

Problem solved

Functional benefit

Brands

• Prevenar: Pneumococcal conjugate vaccines including Prevenar 13 and Prevenar 20 (20-valent pneumococcal polysaccharide conjugate vaccine)
• COMIRNATY
• ABRYSVO
• FSME-IMMUN
• Nimenrix
• Trumenba
• MYCLIC
• VPOIS

Products and services

• COMIRNATY JN.1 / COMIRNATY KP.2 mRNA vaccines for prevention of COVID-19 in individuals from 6 months of age. Contains modified nucleoside mRNA encoding the spike protein of SARS-CoV-2 variants.
• Prevenar 20 (formerly Apexxnar) 20-valent pneumococcal conjugate vaccine (PCV20) for active immunization against invasive pneumococcal diseases and pneumonia caused by Streptococcus pneumoniae in adults from 18 years and children from 6 weeks of age.
• Prevenar 13 13-valent pneumococcal conjugate vaccine (PCV13) for active immunization against invasive pneumococcal diseases and pneumonia in children, adults from 50 years, and immunocompromised patients.
• Nimenrix Conjugate vaccine against meningococcal groups A, C, W-135 and Y for individuals from 6 weeks of age.
• Trumenba Vaccine against meningococcal group B for individuals from 10 years of age.
• FSME-IMMUN Vaccine for active immunization against tick-borne encephalitis, available in 0.5ml and 0.25ml formulations for adults and children.
• ABRYSVO Vaccine against respiratory syncytial virus (RSV) for protection of infants up to 6 months (via maternal vaccination) and adults over 60 years.
• MYCLIC Pen Accessory Reusable accessory for pre-filled pen that simplifies handling for patients who have been recommended the device by their physician.
• Oncology Treatments Portfolio Innovative cancer treatments including tyrosine kinase inhibitors, CDK inhibitors, and therapies for renal cell carcinoma, non-small cell lung cancer, chronic myeloid leukemia, breast cancer, and acute leukemias.
• Cardiovascular Treatments Portfolio Anticoagulant medications including new oral anticoagulants (NOAC) for prevention of venous thromboembolism, stroke prevention, and treatment of DVT and PE.
• Anti-inflammatory Treatments Portfolio Biologic treatments including TNF inhibitors and small molecules such as JAK inhibitors and S1P receptor modulators for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other autoimmune conditions.
• Rare Disease Treatments Portfolio Treatments for rare diseases in hematology, neurological and hereditary metabolic disorders, developed based on over 20 years of experience.
• Anti-infective Portfolio Antibacterial, antifungal, antiviral, and antiparasitic medications including one of the largest anti-infective portfolios on the market.
• Clinical Trials Services Clinical trials conducted in Czech Republic across oncology, vaccines, internal medicine, rare diseases, and inflammatory diseases, registered through SÚKL database and ClinicalTrials.gov.

Quantifiable outcome

• Nearly 60 million people vaccinated with polio vaccine globally
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• BioNTechflagshipStrategic or Co-development Partner · 1 January 2020Strategic partnership with BioNTech for mRNA vaccine development against COVID-19. Pfizer collaborated with BioNTech to develop the Comirnaty vaccine using mRNA technology. This partnership achieved unprecedented speed in vaccine development - under one year from concept to emergency use authorization. This is considered one of the most significant pharmaceutical partnerships in recent history.
• AIFP (Association of Innovative Pharmaceutical Industry)coreStrategic or Co-development PartnerPfizer Czech Republic is a member of AIFP, which brings together 35 pharmaceutical companies focused on research and development of new medicines. Pfizer's General Director MUDr. Pavel Sedláček serves as the chairman of AIFP's board for the 2024-2025 term.
• SÚKL (State Institute for Drug Control)coreTechnology or IntegrationRegulatory partnership with Czech State Institute for Drug Control for clinical trial approvals, drug registration, and pharmacovigilance. Clinical trials in Czech Republic are conducted under SÚKL oversight, and adverse events can be reported through SÚKL's system.
• Faculty of Chemical Technology, University of PardubiceminorStrategic or Co-development PartnerPfizer supports talented students at the Faculty of Chemical Technology, University of Pardubice through awards for beneficial diploma theses in biotechnology and pharmacochemistry. Nearly 30 students have been recognized since 2015.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Novartis Czech Republic: Direct peer: multinational innovative pharmaceutical company operating a Czech subsidiary (Novartis s.r.o.) marketing branded specialty medicines across oncology, cardiology, and immunology. Operates with comparable sales-and-distribution model and competes for the same Czech reimbursement listings.
• Roche Czech Republic: Direct peer: Roche s.r.o. markets branded innovative pharmaceuticals and biologics in Czech Republic across oncology, immunology, and diagnostics. Highly comparable operating footprint and therapeutic-area emphasis.
• Merck (MSD) Czech Republic: Direct peer: MSD Czech Republic (Merck Sharp & Dohme) markets branded innovative vaccines and specialty medicines — Pfizer's Czech General Director began his career at MSD. Comparable commercial model and overlapping portfolio in oncology and vaccines.
• Sanofi Czech Republic: Direct peer: sanofi-aventis s.r.o. markets branded innovative medicines and vaccines (including travel and pediatric vaccines) in Czech Republic. Directly competes in vaccines and immunology, with comparable reimbursement-driven business model.
• GSK Czech Republic: Direct peer: GlaxoSmithKline s.r.o. is a direct competitor in vaccines and specialty pharmaceuticals in Czech Republic, with overlapping respiratory, meningitis, and oncology-adjacent portfolios. Same sales-led distribution model.
• AstraZeneca Czech Republic: Direct peer: AstraZeneca Czech Republic s.r.o. markets branded oncology, cardiovascular, and respiratory medicines in Czech Republic. Overlapping therapeutic areas with Pfizer's oncology and cardiovascular portfolios and same prescription distribution model.
• Johnson & Johnson (Janssen) Czech Republic: Direct peer: Janssen-Cilag s.r.o. markets branded innovative pharmaceuticals in Czech Republic across oncology, immunology, and neurology. Comparable prescription-only distribution model and reimbursement exposure.
• AbbVie Czech Republic: Direct peer: AbbVie s.r.o. markets branded specialty pharmaceuticals including immunology, oncology, and neuroscience products in Czech Republic. Comparable sales-led model with overlap in anti-inflammatory franchises.
• Bayer Czech Republic: Direct peer: Bayer s.r.o. markets branded pharmaceuticals in Czech Republic across cardiology, oncology, and women's health. Comparable prescription distribution channels and physician-facing sales motion.
• Eli Lilly Czech Republic: Direct peer: Eli Lilly Česká republika s.r.o. markets branded innovative medicines in oncology, diabetes, and immunology in Czech Republic. Comparable operating model and reimbursement exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pfizer czech republic